WINTON GROUP Ltd Buys 785 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)

WINTON GROUP Ltd raised its position in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 3.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,768 shares of the company’s stock after acquiring an additional 785 shares during the period. WINTON GROUP Ltd’s holdings in Protagonist Therapeutics were worth $1,033,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Maryland State Retirement & Pension System grew its position in Protagonist Therapeutics by 1.4% in the 4th quarter. Maryland State Retirement & Pension System now owns 20,170 shares of the company’s stock valued at $779,000 after acquiring an additional 278 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Protagonist Therapeutics by 10.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock worth $121,000 after buying an additional 295 shares during the period. Louisiana State Employees Retirement System lifted its holdings in Protagonist Therapeutics by 1.1% during the 4th quarter. Louisiana State Employees Retirement System now owns 28,800 shares of the company’s stock valued at $1,112,000 after buying an additional 300 shares in the last quarter. KBC Group NV boosted its position in Protagonist Therapeutics by 54.4% in the 4th quarter. KBC Group NV now owns 2,093 shares of the company’s stock valued at $81,000 after buying an additional 737 shares during the period. Finally, Moran Wealth Management LLC grew its stake in Protagonist Therapeutics by 6.2% in the 4th quarter. Moran Wealth Management LLC now owns 15,961 shares of the company’s stock worth $616,000 after acquiring an additional 931 shares in the last quarter. Hedge funds and other institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Stock Down 1.1 %

NASDAQ:PTGX opened at $48.88 on Friday. The stock has a market capitalization of $3.00 billion, a price-to-earnings ratio of 18.38 and a beta of 2.34. Protagonist Therapeutics, Inc. has a 52 week low of $24.22 and a 52 week high of $60.60. The firm has a 50 day moving average of $42.54 and a 200 day moving average of $42.88.

Protagonist Therapeutics (NASDAQ:PTGX) last issued its quarterly earnings data on Friday, February 21st. The company reported $1.98 EPS for the quarter, beating the consensus estimate of ($0.09) by $2.07. The firm had revenue of $170.64 million during the quarter, compared to analyst estimates of $56.65 million. Protagonist Therapeutics had a return on equity of 34.68% and a net margin of 52.76%. As a group, analysts expect that Protagonist Therapeutics, Inc. will post 2.43 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on PTGX. BTIG Research set a $73.00 price target on Protagonist Therapeutics in a report on Monday, March 3rd. The Goldman Sachs Group lowered their target price on Protagonist Therapeutics from $43.00 to $38.00 and set a “neutral” rating for the company in a report on Monday, February 24th. StockNews.com lowered Protagonist Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. BMO Capital Markets increased their target price on shares of Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an “outperform” rating in a report on Tuesday, March 11th. Finally, Wedbush restated an “outperform” rating and issued a $70.00 price target on shares of Protagonist Therapeutics in a report on Friday. Two equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $62.56.

Insider Buying and Selling at Protagonist Therapeutics

In other news, CFO Asif Ali sold 24,903 shares of the business’s stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $58.73, for a total transaction of $1,462,553.19. Following the sale, the chief financial officer now directly owns 62,821 shares of the company’s stock, valued at $3,689,477.33. The trade was a 28.39 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director William D. Waddill sold 4,000 shares of the firm’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $54.25, for a total value of $217,000.00. Following the completion of the transaction, the director now owns 13,130 shares of the company’s stock, valued at $712,302.50. This trade represents a 23.35 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 64,776 shares of company stock worth $3,585,010. 5.40% of the stock is owned by insiders.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.